AU2003258060B2 - Potent oncolytic herpes simplex virus for cancer therapy - Google Patents

Info

Publication number

AU2003258060B2

AU2003258060B2 AU2003258060A AU2003258060A AU2003258060B2 AU 2003258060 B2 AU2003258060 B2 AU 2003258060B2 AU 2003258060 A AU2003258060 A AU 2003258060A AU 2003258060 A AU2003258060 A AU 2003258060A AU 2003258060 B2 AU2003258060 B2 AU 2003258060B2

Authority

AU

Australia

Prior art keywords

cell

vector

cells

cell membrane

tumor

Prior art date

2002-03-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 241000700584 Simplexvirus Species 0.000 title claims description 222
• 230000000174 oncolytic effect Effects 0.000 title claims description 155
• 238000011275 oncology therapy Methods 0.000 title claims description 12
• 230000003389 potentiating effect Effects 0.000 title description 18
• 210000004027 cell Anatomy 0.000 claims description 502
• 206010028980 Neoplasm Diseases 0.000 claims description 325
• 108090000623 proteins and genes Proteins 0.000 claims description 209
• 241000700605 Viruses Species 0.000 claims description 202
• 239000013598 vector Substances 0.000 claims description 187
• 210000000170 cell membrane Anatomy 0.000 claims description 144
• 230000000694 effects Effects 0.000 claims description 137
• 150000007523 nucleic acids Chemical group 0.000 claims description 130
• 238000000034 method Methods 0.000 claims description 126
• 230000014509 gene expression Effects 0.000 claims description 125
• 239000000203 mixture Substances 0.000 claims description 108
• 230000000799 fusogenic effect Effects 0.000 claims description 92
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 84
• 230000003612 virological effect Effects 0.000 claims description 84
• 208000015181 infectious disease Diseases 0.000 claims description 74
• 230000035772 mutation Effects 0.000 claims description 65
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
• 102000004169 proteins and genes Human genes 0.000 claims description 46
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
• 230000003211 malignant effect Effects 0.000 claims description 42
• 229920001184 polypeptide Polymers 0.000 claims description 39
• 102000040430 polynucleotide Human genes 0.000 claims description 34
• 108091033319 polynucleotide Proteins 0.000 claims description 34
• 239000002157 polynucleotide Substances 0.000 claims description 34
• 101150090946 UL38 gene Proteins 0.000 claims description 33
• 101150102071 TRX1 gene Proteins 0.000 claims description 31
• 230000010076 replication Effects 0.000 claims description 29
• 230000030741 antigen processing and presentation Effects 0.000 claims description 25
• 230000004927 fusion Effects 0.000 claims description 25
• 230000002458 infectious effect Effects 0.000 claims description 25
• 239000013612 plasmid Substances 0.000 claims description 24
• 230000003362 replicative effect Effects 0.000 claims description 23
• 230000001965 increasing effect Effects 0.000 claims description 22
• 102000003886 Glycoproteins Human genes 0.000 claims description 20
• 108090000288 Glycoproteins Proteins 0.000 claims description 20
• 210000004436 artificial bacterial chromosome Anatomy 0.000 claims description 20
• 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 19
• 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 19
• 238000001415 gene therapy Methods 0.000 claims description 19
• 238000004806 packaging method and process Methods 0.000 claims description 18
• 230000005809 anti-tumor immunity Effects 0.000 claims description 16
• 230000001105 regulatory effect Effects 0.000 claims description 16
• 238000012217 deletion Methods 0.000 claims description 15
• 230000037430 deletion Effects 0.000 claims description 15
• 230000005855 radiation Effects 0.000 claims description 13
• 239000012528 membrane Substances 0.000 claims description 12
• 238000001356 surgical procedure Methods 0.000 claims description 12
• 230000001976 improved effect Effects 0.000 claims description 10
• 238000002512 chemotherapy Methods 0.000 claims description 9
• 238000009169 immunotherapy Methods 0.000 claims description 9
• 230000001177 retroviral effect Effects 0.000 claims description 9
• 210000004962 mammalian cell Anatomy 0.000 claims description 8
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
• 238000012385 systemic delivery Methods 0.000 claims description 6
• 241000712461 unidentified influenza virus Species 0.000 claims description 6
• 101000852024 Gibbon ape leukemia virus Envelope glycoprotein Proteins 0.000 claims description 5
• 102100034353 Integrase Human genes 0.000 claims description 5
• 230000009089 cytolysis Effects 0.000 claims description 5
• 108010078428 env Gene Products Proteins 0.000 claims description 5
• 208000032839 leukemia Diseases 0.000 claims description 5
• 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 4
• 238000002156 mixing Methods 0.000 claims description 4
• 241000282620 Hylobates sp. Species 0.000 claims description 3
• MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 claims 18
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
• 241000699670 Mus sp. Species 0.000 description 80
• 210000001519 tissue Anatomy 0.000 description 77
• 241000713813 Gibbon ape leukemia virus Species 0.000 description 76
• 210000004881 tumor cell Anatomy 0.000 description 73
• 101150101373 fus gene Proteins 0.000 description 66
• 108020004414 DNA Proteins 0.000 description 64
• 102000039446 nucleic acids Human genes 0.000 description 52
• 108020004707 nucleic acids Proteins 0.000 description 52
• 230000001225 therapeutic effect Effects 0.000 description 49
• 101100444512 Synechocystis sp. (strain PCC 6803 / Kazusa) fusB gene Proteins 0.000 description 48
• 101150055609 fusA gene Proteins 0.000 description 48
• 238000000338 in vitro Methods 0.000 description 46
• 201000011510 cancer Diseases 0.000 description 45
• 230000000259 anti-tumor effect Effects 0.000 description 42
• 238000002347 injection Methods 0.000 description 42
• 239000007924 injection Substances 0.000 description 42
• 238000011282 treatment Methods 0.000 description 41
• 230000015572 biosynthetic process Effects 0.000 description 40
• 230000034217 membrane fusion Effects 0.000 description 40
• 235000018102 proteins Nutrition 0.000 description 40
• 230000007246 mechanism Effects 0.000 description 39
• 239000002502 liposome Substances 0.000 description 38
• 239000003795 chemical substances by application Substances 0.000 description 37
• 230000001404 mediated effect Effects 0.000 description 37
• 102000005962 receptors Human genes 0.000 description 37
• 108020003175 receptors Proteins 0.000 description 37
• 238000012384 transportation and delivery Methods 0.000 description 35
• 244000309459 oncolytic virus Species 0.000 description 34
• 238000001727 in vivo Methods 0.000 description 33
• 206010060862 Prostate cancer Diseases 0.000 description 32
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 31
• 206010061535 Ovarian neoplasm Diseases 0.000 description 30
• 206010033128 Ovarian cancer Diseases 0.000 description 29
• 239000000047 product Substances 0.000 description 29
• 230000006870 function Effects 0.000 description 27
• 210000004072 lung Anatomy 0.000 description 26
• 238000002560 therapeutic procedure Methods 0.000 description 25
• 238000012512 characterization method Methods 0.000 description 24
• 239000003623 enhancer Substances 0.000 description 24
• 238000011081 inoculation Methods 0.000 description 24
• 238000003780 insertion Methods 0.000 description 23
• 230000037431 insertion Effects 0.000 description 23
• 210000003501 vero cell Anatomy 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 22
• 238000001890 transfection Methods 0.000 description 22
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
• 230000001939 inductive effect Effects 0.000 description 20
• 231100000350 mutagenesis Toxicity 0.000 description 20
• 230000006378 damage Effects 0.000 description 19
• 201000010099 disease Diseases 0.000 description 19
• 238000007912 intraperitoneal administration Methods 0.000 description 19
• 239000003446 ligand Substances 0.000 description 19
• 208000009889 Herpes Simplex Diseases 0.000 description 18
• 239000000427 antigen Substances 0.000 description 18
• 108091007433 antigens Proteins 0.000 description 18
• 102000036639 antigens Human genes 0.000 description 18
• 239000002609 medium Substances 0.000 description 18
• 238000002703 mutagenesis Methods 0.000 description 18
• 239000002245 particle Substances 0.000 description 18
• 230000009385 viral infection Effects 0.000 description 18
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
• 230000004543 DNA replication Effects 0.000 description 17
• 108020005202 Viral DNA Proteins 0.000 description 17
• 239000012091 fetal bovine serum Substances 0.000 description 17
• 206010061289 metastatic neoplasm Diseases 0.000 description 17
• 239000003981 vehicle Substances 0.000 description 17
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
• 239000000243 solution Substances 0.000 description 16
• 238000013518 transcription Methods 0.000 description 16
• 230000035897 transcription Effects 0.000 description 16
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 230000005865 ionizing radiation Effects 0.000 description 15
• 238000002708 random mutagenesis Methods 0.000 description 15
• 206010027476 Metastases Diseases 0.000 description 14
• 230000037396 body weight Effects 0.000 description 14
• 230000022534 cell killing Effects 0.000 description 14
• 210000002950 fibroblast Anatomy 0.000 description 14
• 206010027458 Metastases to lung Diseases 0.000 description 13
• 239000003550 marker Substances 0.000 description 13
• 230000029812 viral genome replication Effects 0.000 description 13
• 206010006187 Breast cancer Diseases 0.000 description 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• 230000008569 process Effects 0.000 description 12
• 238000007910 systemic administration Methods 0.000 description 12
• 241001529936 Murinae Species 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• 230000008901 benefit Effects 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 239000012634 fragment Substances 0.000 description 11
• 238000010253 intravenous injection Methods 0.000 description 11
• 210000004379 membrane Anatomy 0.000 description 11
• 230000008685 targeting Effects 0.000 description 11
• 230000017105 transposition Effects 0.000 description 11
• 241000701161 unidentified adenovirus Species 0.000 description 11
• 239000013603 viral vector Substances 0.000 description 11
• 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 10
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 10
• 108700020796 Oncogene Proteins 0.000 description 10
• 108091023040 Transcription factor Proteins 0.000 description 10
• 230000006907 apoptotic process Effects 0.000 description 10
• 238000003556 assay Methods 0.000 description 10
• 230000027455 binding Effects 0.000 description 10
• 230000001351 cycling effect Effects 0.000 description 10
• 230000002950 deficient Effects 0.000 description 10
• 210000003527 eukaryotic cell Anatomy 0.000 description 10
• 238000009472 formulation Methods 0.000 description 10
• 230000000977 initiatory effect Effects 0.000 description 10
• 230000002147 killing effect Effects 0.000 description 10
• 230000009401 metastasis Effects 0.000 description 10
• 230000008488 polyadenylation Effects 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 230000004083 survival effect Effects 0.000 description 10
• 230000009466 transformation Effects 0.000 description 10
• 230000014616 translation Effects 0.000 description 10
• 230000005945 translocation Effects 0.000 description 10
• 208000026310 Breast neoplasm Diseases 0.000 description 9
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 9
• 241000588724 Escherichia coli Species 0.000 description 9
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• 102000040945 Transcription factor Human genes 0.000 description 9
• -1 and preferably Chemical compound 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 239000007864 aqueous solution Substances 0.000 description 9
• 230000001413 cellular effect Effects 0.000 description 9
• 238000010276 construction Methods 0.000 description 9
• 238000010348 incorporation Methods 0.000 description 9
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 9
• 229960004844 lovastatin Drugs 0.000 description 9
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 238000012546 transfer Methods 0.000 description 9
• 238000013519 translation Methods 0.000 description 9
• 241001430294 unidentified retrovirus Species 0.000 description 9
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 8
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
• 230000009471 action Effects 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 230000004663 cell proliferation Effects 0.000 description 8
• 230000003833 cell viability Effects 0.000 description 8
• 238000010367 cloning Methods 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
• 230000003013 cytotoxicity Effects 0.000 description 8
• 231100000135 cytotoxicity Toxicity 0.000 description 8
• 238000004520 electroporation Methods 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 239000003112 inhibitor Substances 0.000 description 8
• 150000002632 lipids Chemical class 0.000 description 8
• 230000001394 metastastic effect Effects 0.000 description 8
• 210000003463 organelle Anatomy 0.000 description 8
• 230000002611 ovarian Effects 0.000 description 8
• 210000002307 prostate Anatomy 0.000 description 8
• 230000002829 reductive effect Effects 0.000 description 8
• 108091008146 restriction endonucleases Proteins 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 235000001014 amino acid Nutrition 0.000 description 7
• 150000001413 amino acids Chemical class 0.000 description 7
• 101150067977 ap gene Proteins 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 230000001472 cytotoxic effect Effects 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 239000006185 dispersion Substances 0.000 description 7
• 238000009826 distribution Methods 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 239000001963 growth medium Substances 0.000 description 7
• 210000005260 human cell Anatomy 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 208000014018 liver neoplasm Diseases 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 102000016914 ras Proteins Human genes 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 230000002103 transcriptional effect Effects 0.000 description 7
• 108700028369 Alleles Proteins 0.000 description 6
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
• 241000271566 Aves Species 0.000 description 6
• FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 6
• 206010009944 Colon cancer Diseases 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 6
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• 239000012736 aqueous medium Substances 0.000 description 6
• 210000000481 breast Anatomy 0.000 description 6
• 231100000433 cytotoxic Toxicity 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 210000003494 hepatocyte Anatomy 0.000 description 6
• 230000003463 hyperproliferative effect Effects 0.000 description 6
• 239000000411 inducer Substances 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 230000002101 lytic effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 125000003729 nucleotide group Chemical group 0.000 description 6
• 238000011580 nude mouse model Methods 0.000 description 6
• 210000003200 peritoneal cavity Anatomy 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 238000001959 radiotherapy Methods 0.000 description 6
• 150000003839 salts Chemical class 0.000 description 6
• 238000002741 site-directed mutagenesis Methods 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
• 238000011144 upstream manufacturing Methods 0.000 description 6
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 5
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 5
• 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 102000048850 Neoplasm Genes Human genes 0.000 description 5
• 108700019961 Neoplasm Genes Proteins 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• 208000036142 Viral infection Diseases 0.000 description 5
• 229960004150 aciclovir Drugs 0.000 description 5
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 239000001506 calcium phosphate Substances 0.000 description 5
• 229910000389 calcium phosphate Inorganic materials 0.000 description 5
• 235000011010 calcium phosphates Nutrition 0.000 description 5
• 230000022131 cell cycle Effects 0.000 description 5
• 230000030833 cell death Effects 0.000 description 5
• 230000007910 cell fusion Effects 0.000 description 5
• 230000001086 cytosolic effect Effects 0.000 description 5
• 230000002601 intratumoral effect Effects 0.000 description 5
• 210000003734 kidney Anatomy 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 238000012423 maintenance Methods 0.000 description 5
• 210000003205 muscle Anatomy 0.000 description 5
• 239000002773 nucleotide Substances 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• 108010014186 ras Proteins Proteins 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 239000012679 serum free medium Substances 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 239000002904 solvent Substances 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 210000003462 vein Anatomy 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 108091007914 CDKs Proteins 0.000 description 4
• 108091026890 Coding region Proteins 0.000 description 4
• 102000016736 Cyclin Human genes 0.000 description 4
• 108050006400 Cyclin Proteins 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 230000005778 DNA damage Effects 0.000 description 4
• 231100000277 DNA damage Toxicity 0.000 description 4
• 229920002307 Dextran Polymers 0.000 description 4
• 108010088468 Ebola virus envelope glycoprotein Proteins 0.000 description 4
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
• 102100037907 High mobility group protein B1 Human genes 0.000 description 4
• 101710168537 High mobility group protein B1 Proteins 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 102100034349 Integrase Human genes 0.000 description 4
• 208000007433 Lymphatic Metastasis Diseases 0.000 description 4
• 102000043276 Oncogene Human genes 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 108700005077 Viral Genes Proteins 0.000 description 4
• 210000003815 abdominal wall Anatomy 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000000981 bystander Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 208000029742 colonic neoplasm Diseases 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 239000012636 effector Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 238000001476 gene delivery Methods 0.000 description 4
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
• 229910052737 gold Inorganic materials 0.000 description 4
• 239000010931 gold Substances 0.000 description 4
• 210000003000 inclusion body Anatomy 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 239000006193 liquid solution Substances 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 238000011068 loading method Methods 0.000 description 4
• 210000001165 lymph node Anatomy 0.000 description 4
• 238000000520 microinjection Methods 0.000 description 4
• 230000033607 mismatch repair Effects 0.000 description 4
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
• 239000002644 phorbol ester Substances 0.000 description 4
• 150000003904 phospholipids Chemical class 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 238000001556 precipitation Methods 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 238000000527 sonication Methods 0.000 description 4
• 238000007619 statistical method Methods 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 230000007704 transition Effects 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
• MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
• 101150033839 4 gene Proteins 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 208000003174 Brain Neoplasms Diseases 0.000 description 3
• 241000197194 Bulla Species 0.000 description 3
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
• 241000282552 Chlorocebus aethiops Species 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 230000004568 DNA-binding Effects 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 241000206602 Eukaryota Species 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
• 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 3
• 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 3
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 239000000232 Lipid Bilayer Substances 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 102000052575 Proto-Oncogene Human genes 0.000 description 3
• 108700020978 Proto-Oncogene Proteins 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 108091081024 Start codon Proteins 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 108020004440 Thymidine kinase Proteins 0.000 description 3
• 102000008579 Transposases Human genes 0.000 description 3
• 108010020764 Transposases Proteins 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000001640 apoptogenic effect Effects 0.000 description 3
• 108010084541 asialoorosomucoid Proteins 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 208000002352 blister Diseases 0.000 description 3
• 238000004364 calculation method Methods 0.000 description 3
• 229910002091 carbon monoxide Inorganic materials 0.000 description 3
• 230000025084 cell cycle arrest Effects 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 230000000973 chemotherapeutic effect Effects 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 210000000448 cultured tumor cell Anatomy 0.000 description 3
• 238000011498 curative surgery Methods 0.000 description 3
• 230000001085 cytostatic effect Effects 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• BABWHSBPEIVBBZ-UHFFFAOYSA-N diazete Chemical compound C1=CN=N1 BABWHSBPEIVBBZ-UHFFFAOYSA-N 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 3
• 239000005090 green fluorescent protein Substances 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 238000003306 harvesting Methods 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000002779 inactivation Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 210000003098 myoblast Anatomy 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 108700025694 p53 Genes Proteins 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 208000023958 prostate neoplasm Diseases 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 150000003254 radicals Chemical class 0.000 description 3
• 238000002271 resection Methods 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 230000001360 synchronised effect Effects 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 230000001052 transient effect Effects 0.000 description 3
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
• 229910052721 tungsten Inorganic materials 0.000 description 3
• 239000010937 tungsten Substances 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 239000005723 virus inoculator Substances 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• 101150096316 5 gene Proteins 0.000 description 2
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010003445 Ascites Diseases 0.000 description 2
• 241000713826 Avian leukosis virus Species 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 238000011725 BALB/c mouse Methods 0.000 description 2
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 2
• 239000011547 Bouin solution Substances 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 102000016362 Catenins Human genes 0.000 description 2
• 108010067316 Catenins Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
• 102100024462 Cyclin-dependent kinase 4 inhibitor B Human genes 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 101710121417 Envelope glycoprotein Proteins 0.000 description 2
• 101710091045 Envelope protein Proteins 0.000 description 2
• 102100038595 Estrogen receptor Human genes 0.000 description 2
• 102100029951 Estrogen receptor beta Human genes 0.000 description 2
• 241000714174 Feline sarcoma virus Species 0.000 description 2
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• 208000032612 Glial tumor Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 244000060234 Gmelina philippensis Species 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 206010019695 Hepatic neoplasm Diseases 0.000 description 2
• 108091027305 Heteroduplex Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 241001135569 Human adenovirus 5 Species 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
• 241000712079 Measles morbillivirus Species 0.000 description 2
• 102000003792 Metallothionein Human genes 0.000 description 2
• 108090000157 Metallothionein Proteins 0.000 description 2
• 241000714177 Murine leukemia virus Species 0.000 description 2
• 108010038272 MutS Proteins Proteins 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 108090000556 Neuregulin-1 Proteins 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 2
• 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 2
• 241001452677 Ogataea methanolica Species 0.000 description 2
• 108070000031 Orphan receptors Proteins 0.000 description 2
• 102000016978 Orphan receptors Human genes 0.000 description 2
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
• 108091008606 PDGF receptors Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 108010071690 Prealbumin Proteins 0.000 description 2
• 102000007584 Prealbumin Human genes 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 101710188315 Protein X Proteins 0.000 description 2
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
• 208000007660 Residual Neoplasm Diseases 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 102000054727 Serum Amyloid A Human genes 0.000 description 2
• 108700028909 Serum Amyloid A Proteins 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• 108700026226 TATA Box Proteins 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
• 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000000840 anti-viral effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• 210000002469 basement membrane Anatomy 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000003012 bilayer membrane Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000036770 blood supply Effects 0.000 description 2
• 108010006025 bovine growth hormone Proteins 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 239000003183 carcinogenic agent Substances 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 210000003837 chick embryo Anatomy 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 210000001808 exosome Anatomy 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 229960002963 ganciclovir Drugs 0.000 description 2
• 210000003976 gap junction Anatomy 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000010363 gene targeting Methods 0.000 description 2
• 238000012637 gene transfection Methods 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 108010017007 glucose-regulated proteins Proteins 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000001794 hormone therapy Methods 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 239000012642 immune effector Substances 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 238000002743 insertional mutagenesis Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 238000011031 large-scale manufacturing process Methods 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000006194 liquid suspension Substances 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 201000005202 lung cancer Diseases 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 208000037819 metastatic cancer Diseases 0.000 description 2
• 238000009126 molecular therapy Methods 0.000 description 2
• 239000003471 mutagenic agent Substances 0.000 description 2
• 231100000707 mutagenic chemical Toxicity 0.000 description 2
• 230000000869 mutational effect Effects 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 229940053128 nerve growth factor Drugs 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 238000001543 one-way ANOVA Methods 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 230000005522 programmed cell death Effects 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000003439 radiotherapeutic effect Effects 0.000 description 2
• 108700042226 ras Genes Proteins 0.000 description 2
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000028617 response to DNA damage stimulus Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 239000002356 single layer Substances 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 239000005495 thyroid hormone Substances 0.000 description 2
• 229940036555 thyroid hormone Drugs 0.000 description 2
• 102000004217 thyroid hormone receptors Human genes 0.000 description 2
• 108090000721 thyroid hormone receptors Proteins 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 230000007442 viral DNA synthesis Effects 0.000 description 2
• 230000007482 viral spreading Effects 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• 238000000316 virotherapy Methods 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
• XAXNKAGAUFXFDO-JVJDXIHNSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-chlorophenyl)prop-2-enamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)NC(=O)\C=C\C=2C=CC(Cl)=CC=2)CC1)O)CC1CC1 XAXNKAGAUFXFDO-JVJDXIHNSA-N 0.000 description 1
• VVJYUAYZJAKGRQ-BGZDPUMWSA-N 1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)C1 VVJYUAYZJAKGRQ-BGZDPUMWSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• MEOVPKDOYAIVHZ-UHFFFAOYSA-N 2-chloro-1-(1-methylpyrrol-2-yl)ethanol Chemical compound CN1C=CC=C1C(O)CCl MEOVPKDOYAIVHZ-UHFFFAOYSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 101150012307 78 gene Proteins 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
• 241000589158 Agrobacterium Species 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 238000010953 Ames test Methods 0.000 description 1
• 231100000039 Ames test Toxicity 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 102100038778 Amphiregulin Human genes 0.000 description 1
• 108010033760 Amphiregulin Proteins 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• 241000207875 Antirrhinum Species 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 241000282708 Aotus <primate> Species 0.000 description 1
• 241000219194 Arabidopsis Species 0.000 description 1
• 101100178208 Arabidopsis thaliana HMGB4 gene Proteins 0.000 description 1
• 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
• 101000707172 Arabidopsis thaliana Protein SAWADEE HOMEODOMAIN HOMOLOG 1 Proteins 0.000 description 1
• 241000203069 Archaea Species 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 241000713840 Avian erythroblastosis virus Species 0.000 description 1
• 241000713838 Avian myeloblastosis virus Species 0.000 description 1
• 241000713842 Avian sarcoma virus Species 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 102100037674 Bis(5'-adenosyl)-triphosphatase Human genes 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
• 108010062802 CD66 antigens Proteins 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 108010055166 Chemokine CCL5 Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 102000003910 Cyclin D Human genes 0.000 description 1
• 108090000259 Cyclin D Proteins 0.000 description 1
• 108010058546 Cyclin D1 Proteins 0.000 description 1
• 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
• 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
• 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 102000003849 Cytochrome P450 Human genes 0.000 description 1
• 102000000311 Cytosine Deaminase Human genes 0.000 description 1
• 108010080611 Cytosine Deaminase Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 108700010025 DRD1 Proteins 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
• 241000275449 Diplectrum formosum Species 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
• 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 108010003751 Elongin Proteins 0.000 description 1
• 102000004662 Elongin Human genes 0.000 description 1
• 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
• 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
• 102100039328 Endoplasmin Human genes 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 206010049466 Erythroblastosis Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 241001522878 Escherichia coli B Species 0.000 description 1
• 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
• 241001524679 Escherichia virus M13 Species 0.000 description 1
• 241000713859 FBR murine osteosarcoma virus Species 0.000 description 1
• 101150021185 FGF gene Proteins 0.000 description 1
• 206010073153 Familial medullary thyroid cancer Diseases 0.000 description 1
• 201000004939 Fanconi anemia Diseases 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000020897 Formins Human genes 0.000 description 1
• 108091022623 Formins Proteins 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
• 108091006109 GTPases Proteins 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 230000010558 Gene Alterations Effects 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
• 101150109586 Gk gene Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 101800000342 Glycoprotein C Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 108091008603 HGF receptors Proteins 0.000 description 1
• 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
• 102000049982 HMGA2 Human genes 0.000 description 1
• 108700039143 HMGA2 Proteins 0.000 description 1
• 101150112743 HSPA5 gene Proteins 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 208000016096 Hereditary retinoblastoma Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000980919 Homo sapiens Cyclin-dependent kinase 4 inhibitor B Proteins 0.000 description 1
• 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
• 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
• 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
• 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 1
• 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
• 101000835893 Homo sapiens Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
• 101000621344 Homo sapiens Protein Wnt-2 Proteins 0.000 description 1
• 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 101900331644 Human herpesvirus 1 Triplex capsid protein VP19C Proteins 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102100033501 Interleukin-32 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 102100039648 Lactadherin Human genes 0.000 description 1
• 108010000851 Laminin Receptors Proteins 0.000 description 1
• 102000002297 Laminin Receptors Human genes 0.000 description 1
• 101710128836 Large T antigen Proteins 0.000 description 1
• 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 description 1
• 241000209510 Liliopsida Species 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 241001625930 Luria Species 0.000 description 1
• 108700005089 MHC Class I Genes Proteins 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010031099 Mannose Receptor Proteins 0.000 description 1
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
• 206010027457 Metastases to liver Diseases 0.000 description 1
• 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
• 101100493631 Mus musculus Bcl2l2 gene Proteins 0.000 description 1
• 101100007124 Mus musculus Col11a2 gene Proteins 0.000 description 1
• 101001058457 Mus musculus Glycosylation-dependent cell adhesion molecule 1 Proteins 0.000 description 1
• 101000869722 Mus musculus Sodium-dependent phosphate transporter 2 Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 206010029098 Neoplasm skin Diseases 0.000 description 1
• 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 1
• 102400000058 Neuregulin-1 Human genes 0.000 description 1
• 102000048238 Neuregulin-1 Human genes 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 101150054854 POU1F1 gene Proteins 0.000 description 1
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 206010033964 Parathyroid tumour benign Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108010087702 Penicillinase Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
• 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 101710114878 Phospholipase A-2-activating protein Proteins 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 description 1
• 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 208000000474 Poliomyelitis Diseases 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 102100038358 Prostate-specific antigen Human genes 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010076504 Protein Sorting Signals Proteins 0.000 description 1
• 102100022805 Protein Wnt-2 Human genes 0.000 description 1
• 102100027584 Protein c-Fos Human genes 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
• 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
• 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
• 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 101800001693 R-peptide Proteins 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 108091005682 Receptor kinases Proteins 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 241001068263 Replication competent viruses Species 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 108091006788 SLC20A1 Proteins 0.000 description 1
• 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 241000607715 Serratia marcescens Species 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 102100029797 Sodium-dependent phosphate transporter 1 Human genes 0.000 description 1
• 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 101710151717 Stress-related protein Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 108060008245 Thrombospondin Proteins 0.000 description 1
• 102000002938 Thrombospondin Human genes 0.000 description 1
• 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
• 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
• 108700009124 Transcription Initiation Site Proteins 0.000 description 1
• 102100023132 Transcription factor Jun Human genes 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102000013394 Troponin I Human genes 0.000 description 1
• 108010065729 Troponin I Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108010091356 Tumor Protein p73 Proteins 0.000 description 1
• 102000018252 Tumor Protein p73 Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 102100039094 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 101150104684 UL44 gene Proteins 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 description 1
• 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 108070000030 Viral receptors Proteins 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 1
• 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
• 206010048218 Xeroderma Diseases 0.000 description 1
• 235000007244 Zea mays Nutrition 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 108010084455 Zeocin Proteins 0.000 description 1
• VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
• YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 208000019790 abdominal distention Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 210000005221 acidic domain Anatomy 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 210000001053 ameloblast Anatomy 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000009167 androgen deprivation therapy Methods 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003602 anti-herpes Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 230000007416 antiviral immune response Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 210000004507 artificial chromosome Anatomy 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 238000011717 athymic nude mouse Methods 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000003416 augmentation Effects 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 239000013602 bacteriophage vector Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000036983 biotransformation Effects 0.000 description 1
• 108010005713 bis(5'-adenosyl)triphosphatase Proteins 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 231100000260 carcinogenicity Toxicity 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003850 cellular structure Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 210000003763 chloroplast Anatomy 0.000 description 1
• 230000008711 chromosomal rearrangement Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000009096 combination chemotherapy Methods 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000002681 cryosurgery Methods 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000000120 cytopathologic effect Effects 0.000 description 1
• 230000021040 cytoplasmic transport Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 108020001096 dihydrofolate reductase Proteins 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000013024 dilution buffer Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 230000001094 effect on targets Effects 0.000 description 1
• 230000003028 elevating effect Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 230000006846 excision repair Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 201000008949 familial retinoblastoma Diseases 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 101150078861 fos gene Proteins 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 101150002378 gC gene Proteins 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 108010084724 gibbon ape leukemia virus receptor Proteins 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000003630 growth substance Substances 0.000 description 1
• 101150028578 grp78 gene Proteins 0.000 description 1
• 229960000789 guanidine hydrochloride Drugs 0.000 description 1
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 108700039582 histidine triad Proteins 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 230000006951 hyperphosphorylation Effects 0.000 description 1
• 206010021198 ichthyosis Diseases 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 102000027411 intracellular receptors Human genes 0.000 description 1
• 108091008582 intracellular receptors Proteins 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 238000002430 laser surgery Methods 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 238000000464 low-speed centrifugation Methods 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 239000002923 metal particle Substances 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 230000003228 microsomal effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 244000309715 mini pig Species 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000002969 morbid Effects 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 231100000299 mutagenicity Toxicity 0.000 description 1
• 230000007886 mutagenicity Effects 0.000 description 1
• 101150008049 mx gene Proteins 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 230000004987 nonapoptotic effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000008689 nuclear function Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 108091008796 oncogenic growth factors Proteins 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
• 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
• 108700042657 p16 Genes Proteins 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000011499 palliative surgery Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 201000003686 parathyroid adenoma Diseases 0.000 description 1
• 208000014643 parathyroid gland adenoma Diseases 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229950009506 penicillinase Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
• QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
• 230000000379 polymerizing effect Effects 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 238000011176 pooling Methods 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• 230000001566 pro-viral effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229930185346 proliferin Natural products 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000002407 reforming Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 210000001625 seminal vesicle Anatomy 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 125000005630 sialyl group Chemical group 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000009131 signaling function Effects 0.000 description 1
• HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
• 229910010271 silicon carbide Inorganic materials 0.000 description 1
• 108700021652 sis Genes Proteins 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 230000008410 smoothened signaling pathway Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 108090000586 somatostatin receptor 2 Proteins 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 108091007196 stromelysin Proteins 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 238000009121 systemic therapy Methods 0.000 description 1
• 101150047061 tag-72 gene Proteins 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000005167 vascular cell Anatomy 0.000 description 1
• 201000010653 vesiculitis Diseases 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 230000007501 viral attachment Effects 0.000 description 1
• 230000007502 viral entry Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1